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Abstract
Introduction: Every eye with central retinal vein occlusion (CRVO) is at risk for developing
neovascular glaucoma (NVG). Vascular endothelial growth factor (VEGF) has been shown to play
a key role in the development of NVG in CRVO. Bevacizumab (Avastin; Genentech, San Francisco,
CA) is a recombinant monoclonal antibody binding all isoforms of VEGF. Several studies have
demonstrated intravitreal bevacizumab-induced regression of iris and angle neovascularisation
associated with NVG.
Case presentation: A 74 year old female presented with acute onset decreased vision in the right
eye. Ophthalmic exam revealed acute non-ischemic CRVO in the right eye. A month later, follow
up exam showed progression into ischemic CRVO and secondary NVG, which was successfully
treated with intravitreal Bevacizumab followed by pan retinal photocoagulation (PRP).
Conclusion: Our case report highlights the use of intravitreal Bevacizumab in combination with
PRP for the treatment of NVG secondary to CRVO.
Introduction
Retinal vein occlusion (RVO) is the most common retinal
vascular disease after diabetic retinopathy with a cumula-
tive 10-year incidence of 1.6% [1]. Central retinal vein
occlusion (CRVO) is a disease of the elderly patients (age
>50 years old). Major risk factors are hypertension, diabe-
tes, and atherosclerosis. Other risk factors are glaucoma,
syphilis, sarcoidosis, vasculitis, increased intraorbital or
intraocular pressure, hyphema, hyperviscosity syndromes
(polycythemia, multiple myeloma, Waldenstrom's mac-
roglobulinemia, and leukemia), high homocysteine lev-
els, sickle cell, and HIV [2].
Every eye with CRVO is at risk for developing neovascular
glaucoma (NVG). Lowering intraocular pressure helps to
improve retinal circulation in an eye with CRVO [3], and
there is a 10% risk for development of RVO in the fellow
eye [4].
Risk factors for developing neovascular iris in patients
with CRVO are the amount of nonperfused retina, extent
of retinal hemorrhages, male sex, and central vein occlu-
sion of less than one month duration [5]. Visual acuity in
patients with CRVO at baseline is a strong predictor for
the development of iris and angle neovascularisation, as is
the amount of nonperfusion seen by fluorescein angi-
ogram [6].
Established modalities for the treatment of NVG include
panretinal photocoagulation (PRP) to reduce the produc-
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medical and surgical control of elevated intraocular pres-
sure. Bevacizumab (Avastin; Genentech, San Francisco,
CA) is a recombinant monoclonal antibody binding all
isoforms of vascular endothelial growth factor (VEGF).
Several studies have demonstrated intravitreal bevacizu-
mab-induced regression of iris and angle neovascularisa-
tion associated with NVG with promising results [7-14].
We present a patient with history of age-related macular
degeneration (AMD) and polycythemia vera who devel-
oped CRVO, which subsequently got complicated by
NVG, and was successfully treated with intravitreal injec-
tion of Bevacizumab followed by PRP.
Case presentation
A 74 year old Caucasian female presented to the Eye clinic
complaining of blurry vision in the right eye that started
one week prior to presentation.
Past medical history is significant for hypertension, dysli-
pidemia, diabetes, and polycythemia vera. Past ocular his-
tory is significant for age related macular degeneration
(AMD), cataract extraction and intraocular lens placement
in both eyes. Most recent lab check showed hemoglobin
of 16.5 gram per deciliter, and Hematocrit of 48.8%.
Ophthalmic exam revealed best corrected visual acuity of
20/CF in the right eye (OD), and 20/50 in the left eye
(OS) [Baseline visual acuity was 20/30 OD, and 20/50
OS]. Pupil exam showed fixed irregular non-reactive right
pupil that measured 4 mm. Left pupil was round, and
reactive to light. Intraocular pressure measured 17 mm Hg
on the right, and 14 mm Hg on the left. Slit-lamp exam
showed normal lid and lashes, white conjunctiva, clear
cornea, clear and deep anterior chamber bilaterally, and
pseudophakia bilaterally (posterior capsule intraocular
lens). Dilated fundus exam of the right eye showed mild
disk edema, the presence of venous tortuosity with disten-
sion. There were moderate intraretinal hemorrhages
throughout the posterior pole with a greater amount of
hemorrhages in the peripapillary region (Figure 1).
Dilated fundus exam of the left eye showed normal cup to
disc ratio with normal disc and vessels, the presence of
drusen with RPE changes and focal areas of geographic
atrophy in the macula consistent with macular degenera-
tion (Figure 2). The patient declined fluroescein angi-
ogram.
Based on the clinical history and ophthalmic exam, the
patient was diagnosed with acute non-ischemic central
retinal vein occlusion (CRVO) in the right eye. The patient
was instructed to follow closely in the Eye clinic, to per-
form gonioscopy and undilated examination of the iris on
each visit to rule out NVG and iris neovascularization.
Follow-up exam one month later revealed visual acuity of
20/CF with no improvement on the right, and 20/50 on
the left. Introcular pressures were 25 mmHg on the right,
and15 mmHg on the left. Gonioscopy revealed angle neo-
vascularization in the right eye. Dilated fundus exam was
unchanged. The patient was diagnosed with NVG second-
ary to CRVO in the right eye.
She underwent an intravitreal Bevacizumab injection
(1.25 mg/0.05 mL) and PRP in the right eye with an inter-
val of one week to treat NVG. One week post PRP exam
showed pressures of 18 mmHg OD and 15 mmHg OS.
Discussion
CRVO is characterized by vascular obstruction leading to
intraretinal hemorrhage, exudation of fluid, and variable
degrees of ischemia. The vascular damage associated with
the occlusion is accompanied by complex cellular and
inflammatory reactions. A disturbed balance of ang-
iogenic and inflammatory cytokines in ocular fluid has
been observed in RVO [15-18].
VEGF is a known chemoattractant for macrophages and
monocytes, a key factor in angiogenesis and increased vas-
cular permeability. VEGF stimulates neovascularization
and the formation of macular edema in CRVO [19]. Funk
et al. found an increased VEGF levels in the aqueous
humor of patients with CRVO. They also demonstrated
measurable levels of VEGF in the control group providing
evidence for a physiological expression of this angiogenic
factor in the human eye [18]. They supposed that cytokine
levels in aqueous humor should reflect levels in the vitre-
ous, as correlation of aqueous and vitreous levels has been
described in the past [20]. Additionally, there has been no
correlation between cytokine levels in the aqueous humor
and in plasma [15,20], providing evidence for intraocular
sources.
VEGF mRNA up-regulation has been observed in the
human retina in patients with CRVO [21] as has a correla-
tion of the severity of macular edema with aqueous and
vitreous levels of VEGF [20]. Funk et al. concluded that
initial monthly treatment with anti-VEGF in CRVO
reduced VEGF levels to undetectable values and below
physiologic levels. The changes of intraocular VEGF levels
were also associated with disease activity [18].
NVG secondary to CRVO is a devastating type of glau-
coma with a poor prognosis. It is caused by neovasculari-
sation of the iris and anterior chamber angle with
eventual angle closure and intractable elevation of
intraocular pressure (IOP) [14].Page 2 of 4
(page number not for citation purposes)
Cases Journal 2009, 2:176 http://www.casesjournal.com/content/2/1/176The management of NVG includes lowering IOP (often
surgically) and PRP, which reduces the production of
vasoproliferative factors by ischaemic retina and can
induce regression of anterior segment neovascularisation.
Bevacizumab is a neutralizing anti-VEGF recombinant
humanized monoclonal antibody. Intravitreal bevacizu-
mab is now a frequently used adjunct for the treatment of
VEGF-mediated NVG in CRVO [7-14]. Eyes treated with
intravitreal bevacizumab should be monitored closely
because surgery for IOP control and repeat bevacizumab
injections are often necessary, regardless of initial angle
status[14]. Bevacizumab should be instituted promptly
after diagnosis, before irreversible anatomic and func-
tional damage occurs [22].
Ehlers et al. compared combination intravitreal bevacizu-
mab/PRP for the treatment of NVG with PRP alone. They
concluded that the combination treatment resulted in
more rapid decrease in IOP. In addition, the combination
group had increased frequency and rapidity of regression
of neovascularization [23].
Wakabayashi et al. studied 41 eyes with iris neovasculari-
zation (INV) or neovascular NVG secondary to ischemic
retinal disorders. Patients received intravitreal Bevacizu-
mab (1 mg) as the initial treatment for INV or NVG and
were followed up for at least 6 months. Intravitreal beva-
cizumab was well tolerated, effectively stabilized INV
activity, and controlled IOP in patients with INV alone
and early-stage NVG without angle closure. In advanced
NVG, Bevacizumab cannot control IOP but may be used
adjunctively to improve subsequent surgical results [24].
Conclusion
Our case illustrates an interesting presentation of CRVO
in an old lady with multiple risk factors including poly-
cythemia vera, hypertension, diabetes, and atherosclero-
sis. The patient progressed to an ischemic CRVO with
secondary NVG. Her risk factors to develop NVG second-
ary to CRVO were the extent of retinal hemorrhages,
CRVO of less than one month duration, and counting fin-
ger visual acuity upon initial presentation with CRVO. She
was successfully treated with intravitreal Bevacizumab
injection followed by PRP. The neovascularization
regressed, and the intraocluar pressure was controlled.
In summary, our case report highlights the use of intravit-
real Bevacizumab in combination with PRP in the treat-
ment of NVG secondary to CRVO.
Consent
Written informed consent was obtained from the patient
for publication of this case report and accompanying
images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.
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Color fundus photograph of the left eye is showing 
the presence of drusen with RPE changes and focal 
areas of geographic atrophy in the macula consistent 
with macular degeneration. Cup to disk ratio is 0.3 in the 
left eye with normal disk and vessels.
Color fundus photograph of the right eye is showing the presence of venous tortuosity with distensionFigu e 1
Color fundus photograph of the right eye is showing 
the presence of venous tortuosity with distension. 
There are moderate intraretinal hemorrhages throughout 
the posterior pole with a greater amount of hemorrhages in 
a peripapillary region. Mild disk edema appears to be present.Page 3 of 4
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